TAX1BP3: A Drug Target / Disease Biomarker (G30851)

Target Name: TAX1BP3

NCBI ID: G30851

TAX1BP3

TAX1BP3: A Drug Target / Disease Biomarker

Taxolimab (TAX1BP3) is a monoclonal antibody targeting the protein BSP3, which is a key regulator of cell survival and proliferation. TheTAX1BP3 is being investigated as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

TAX1BP3 is a human monoclonal antibody that was developed by the Broad Institute of MIT and Harvard. It is designed to selectively bind to BSP3, a protein that is expressed in a variety of tissues and cell types, including cancer cells, neurons, and immune cells. TheTAX1BP3 is able to inhibit the activity of BSP3, which can lead to the collapse of cancer cells and the death of neurodegenerative disease patients.

One of the key advantages of TAX1BP3 is its ability to cross the blood-brain barrier, which is a barrier that separates the brain from the rest of the body. This allows researchers to study the effects of TAX1BP3 on brain cells and tissues, which is important for understanding how the drug may work in these settings.

In preclinical studies, TAX1BP3 has been shown to be effective in a variety of settings. For example, it has been shown to be effective in treating various types of cancer, including breast cancer, lung cancer, and colorectal cancer. TheTAX1BP3 has also been shown to be effective in treating neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Another potential advantage of TAX1BP3 is its ability to target a specific protein, which makes it more effective than many other treatments. By targeting BSP3, TAX1BP3 is able to reduce the production of BSP3, which can lead to the collapse of cancer cells and the death of neurodegenerative disease patients.

In addition to its potential as a drug, TAX1BP3 also has potential as a biomarker. By measuring the levels of BSP3 in cancer cells and neurodegenerative disease tissues, researchers can monitor the effectiveness of TAX1BP3 and determine how well the drug is working. This can be an important tool for understanding the mechanisms of TAX1BP3 and for developing new treatments.

Overall, TAX1BP3 is a promising drug target and biomarker that has the potential to revolutionize the treatment of cancer and neurodegenerative diseases. Further research is needed to fully understand the effects of TAX1BP3 and to develop new treatments.

Protein Name: Tax1 Binding Protein 3

Functions: May regulate a number of protein-protein interactions by competing for PDZ domain binding sites. Binds CTNNB1 and may thereby act as an inhibitor of the Wnt signaling pathway. Competes with LIN7A for KCNJ4 binding, and thereby promotes KCNJ4 internalization. May play a role in the Rho signaling pathway. May play a role in activation of CDC42 by the viral protein HPV16 E6

The "TAX1BP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAX1BP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets